GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (HKSE:00460) » Definitions » Beneish M-Score

Sihuan Pharmaceutical Holdings Group (HKSE:00460) Beneish M-Score : -2.63 (As of Jun. 20, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.63 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Sihuan Pharmaceutical Holdings Group's Beneish M-Score or its related term are showing as below:

HKSE:00460' s Beneish M-Score Range Over the Past 10 Years
Min: -4.6   Med: -2.66   Max: -1.74
Current: -2.63

During the past 13 years, the highest Beneish M-Score of Sihuan Pharmaceutical Holdings Group was -1.74. The lowest was -4.60. And the median was -2.66.


Sihuan Pharmaceutical Holdings Group Beneish M-Score Historical Data

The historical data trend for Sihuan Pharmaceutical Holdings Group's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sihuan Pharmaceutical Holdings Group Beneish M-Score Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.60 -1.74 -2.36 -3.32 -2.63

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.36 - -3.32 - -2.63

Competitive Comparison of Sihuan Pharmaceutical Holdings Group's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sihuan Pharmaceutical Holdings Group's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's Beneish M-Score falls into.



Sihuan Pharmaceutical Holdings Group Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sihuan Pharmaceutical Holdings Group for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2533+0.528 * 0.9794+0.404 * 1.011+0.892 * 0.8355+0.115 * 1.4891
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0439+4.679 * -0.021976-0.327 * 1.5396
=-2.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was HK$1,143 Mil.
Revenue was HK$2,035 Mil.
Gross Profit was HK$1,417 Mil.
Total Current Assets was HK$6,786 Mil.
Total Assets was HK$12,617 Mil.
Property, Plant and Equipment(Net PPE) was HK$3,109 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$247 Mil.
Selling, General, & Admin. Expense(SGA) was HK$997 Mil.
Total Current Liabilities was HK$4,492 Mil.
Long-Term Debt & Capital Lease Obligation was HK$1,047 Mil.
Net Income was HK$-59 Mil.
Gross Profit was HK$0 Mil.
Cash Flow from Operations was HK$218 Mil.
Total Receivables was HK$1,092 Mil.
Revenue was HK$2,436 Mil.
Gross Profit was HK$1,661 Mil.
Total Current Assets was HK$7,315 Mil.
Total Assets was HK$13,558 Mil.
Property, Plant and Equipment(Net PPE) was HK$3,348 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$413 Mil.
Selling, General, & Admin. Expense(SGA) was HK$1,143 Mil.
Total Current Liabilities was HK$2,829 Mil.
Long-Term Debt & Capital Lease Obligation was HK$1,037 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1143.151 / 2035.018) / (1091.707 / 2435.766)
=0.56174 / 0.448199
=1.2533

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1661.204 / 2435.766) / (1417.148 / 2035.018)
=0.682005 / 0.696381
=0.9794

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (6785.536 + 3108.551) / 12617.21) / (1 - (7314.912 + 3348.275) / 13557.532)
=0.215826 / 0.213486
=1.011

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2035.018 / 2435.766
=0.8355

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(412.969 / (412.969 + 3348.275)) / (247.449 / (247.449 + 3108.551))
=0.109796 / 0.073733
=1.4891

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(996.668 / 2035.018) / (1142.774 / 2435.766)
=0.489759 / 0.469164
=1.0439

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1046.763 + 4491.933) / 12617.21) / ((1036.992 + 2828.638) / 13557.532)
=0.438979 / 0.285128
=1.5396

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-59.083 - 0 - 218.195) / 12617.21
=-0.021976

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sihuan Pharmaceutical Holdings Group has a M-score of -2.63 suggests that the company is unlikely to be a manipulator.


Sihuan Pharmaceutical Holdings Group Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Sihuan Pharmaceutical Holdings Group's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Sihuan Pharmaceutical Holdings Group (HKSE:00460) Business Description

Traded in Other Exchanges
Address
Zhubang 2000 Business Centre, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Digestive System, Anti-Infective, metabolism, Respiratory, Neurology, and Others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others to provide non- or minimally invasive medical aesthetics comprehensive solutions; the innovative medicine and other medicine segments; and the generic medicine segment.
Executives
Che Fengsheng 2201 Interest of corporation controlled by you
Guo Weicheng 2201 Interest of corporation controlled by you
Meng Xianhui 2201 Interest of corporation controlled by you
Zhang Jionglong 2201 Interest of corporation controlled by you
Mingyao Capital Limited 2401 A concert party to an agreement to buy shares
Network Victory Limited 2401 A concert party to an agreement to buy shares
Proper Process International Limited 2401 A concert party to an agreement to buy shares
Successmax Global Holdings Limited 2101 Beneficial owner
Victory Faith International Limited 2401 A concert party to an agreement to buy shares
Ubs Tc (jersey) Ltd 2301 Trustee
Ubs Trustees (cayman) Ltd. 2301 Trustee
Smart Top Overseas Limited 2501 Other
Plenty Gold Enterprises Limited 2307 Founder of a discretionary trust who can infl

Sihuan Pharmaceutical Holdings Group (HKSE:00460) Headlines

No Headlines